We hypothesize that metastatic PCa patients with poorly differentiated tumors, marked by reduced AR activity and low neuroendocrine differentiation, a mesenchymal-like phenotype, may represent this mesothelin-expressing subgroup [71]. Here, MSLN is linked to posterior cortical atrophy.